Episurf Medical (Nasdaq: EPIS B) today communicates that the publication with the title "Patient specific metal implants for focal chondral and osteochondral lesions in the knee - Excellent clinical results at 2 years" from a European multicentre study with 24 months' follow-up of 80 Episealer® Knee implant patients, which is accepted for publication in the scientific journal Knee Surgery, Sports Traumatology, Arthroscopy (KSSTA), is now available online. Link to the publication: https://rdcu.be/b8fin
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.
(c) 2020 Cision. All rights reserved., source Press Releases - English